V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004555 | 10002878 | 1.71 | null | Disease modification (D) | 2016-11-04 | 2017-05-15 | BORTEZOMIB + THALIDOMIDE | 2 | N | 10533748 | CODOX M |
| 10004556 | 10002879 | 1.66 | 116 | Palliative (P) | 2017-03-01 | 2017-03-01 | Trastuzumab 21 day loading dose | N | N | 10533910 | PMITCEBO R |
| 10004557 | 10002880 | 1.51 | 78.7 | Disease modification (D) | 2017-09-17 | 2017-10-16 | FEC 100 + DOCETAXEL + TRASTUZUMAB | 02 | N | 10534247 | DABRAFENIB + TRAMETINIB |
| 10004558 | 10002880 | 1.67 | 88.3 | Curative (C) | 2016-08-14 | 2016-08-28 | Pazopanib | N | N | 10534247 | BUSULPHAN |
| 10004559 | 10002881 | 1.73 | 82.3 | Curative (C) | 2018-09-11 | 2018-09-11 | Gefitinib: 1 to 2 & 4 onwards | 02 | N | 10534329 | BORTEZOMIB + THALIDOMIDE |
| 10004560 | 10006665 | 1.75 | 68.8 | null | 2018-12-18 | 2018-12-18 | RUXOLITINIB | 99 | N | 10534443 | IBRUTINIB |
| 10004561 | 10002882 | 1.75 | 70.2 | Curative (C) | 2018-07-02 | 2018-07-03 | Sunitinib | N | N | 10534514 | CISPLATIN + FLUOROURACIL |
| 10004562 | 10002882 | 1.57 | 60.8 | Curative (C) | 2014-11-04 | 2014-11-07 | FEC + DOCETAXEL + TRASTUZUMAB | 2 | N | 10534514 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN |
| 10004563 | 10002882 | 1.81 | 96.8 | Palliative (P) | null | 2017-08-02 | Cape+Cisplatin+Trastuzumab Load | N | null | 10534514 | CHOP R + METHOTREXATE |
| 10004564 | 10002883 | 1.66 | 98 | Adjuvant (A) | 2018-11-10 | 2018-11-28 | R Chlorambucil | null | N | 10534701 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10004565 | 10002884 | 1.42 | 66 | Palliative (P) | 2018-05-25 | 2018-05-27 | Trastuzumab Subcutaneous | N | N | 10534712 | DA |
| 10004568 | 10002886 | 1.61 | 73.9 | Palliative (P) | 2016-11-01 | 2016-11-02 | Panitumumab | N | N | 10534927 | NOT MATCHED |
| 10004569 | 10002887 | 1.8 | 83 | Palliative (P) | 2016-04-26 | 2016-05-06 | ANAGRELIDE | 02 | N | 10535061 | PERM TRIAL |
| 10004570 | 10002887 | 1.73 | 53.6 | Adjuvant (A) | 2016-12-12 | 2016-12-17 | CYCLOPHOSPHAMIDE + PACLITAXEL | 02 | N | 10535061 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10004571 | 10002888 | 1.8 | 69.2 | Curative (C) | 2016-09-26 | 2016-10-12 | EP | N | N | 10535113 | VISMODEGIB |
| 10004572 | 10002889 | 1.77 | 72.1 | Palliative (P) | 2017-02-27 | 2017-02-27 | DABRAFENIB + TRAMETINIB | 02 | N | 10535352 | MYELOMA XI TRIAL |
| 10004573 | 10002890 | 0 | 65.8 | Palliative (P) | 2017-05-30 | 2017-06-11 | LOMUSTINE + PROCARBAZINE + VINCRISTINE | N | N | 10535409 | REMODL TRIAL |
| 10004574 | 10002891 | 1.72 | 69.1 | Curative (C) | 2014-07-16 | 2014-07-16 | MITOMYCIN | Y | Y | 10535532 | CETUXIMAB + IRINOTECAN + MDG |
| 10004575 | 10002892 | 1.88 | 67.5 | Adjuvant (A) | 2017-12-18 | 2017-12-18 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | 10535535 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 10004576 | 10002892 | 1.7 | 0 | Adjuvant (A) | 2015-12-30 | 2016-01-06 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | Y | N | 10535535 | CARBOPLATIN + RT |
| 10004577 | 10002892 | 1.47 | 79 | Palliative (P) | 2016-05-26 | 2016-06-08 | ACELARATE Trial | N | N | 10535535 | VINORELBINE |
| 10004578 | 10002892 | null | 90 | Palliative (P) | 2017-06-01 | 2017-06-01 | Capecitabine + Mitomycin | N | N | 10535535 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10004579 | 10002892 | 1.66 | 91 | Palliative (P) | 2017-10-12 | 2017-10-13 | Cetuximab + Radiotherapy Load | Y | N | 10535535 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004580 | 10002893 | 1.66 | 60 | Disease modification (D) | 2018-04-01 | 2018-05-05 | Mitomycin Intravesical | N | Y | 10535816 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN |
| 10004581 | 10002894 | null | 60.4 | Adjuvant (A) | 2017-07-15 | 2017-08-11 | CHLORAMBUCIL + OBINUTUZUMAB | N | Y | 10535889 | ERLOTINIB |
| 10004582 | 10002894 | 1.57 | 68.3 | Adjuvant (A) | 2018-11-22 | 2018-12-24 | Capecitabine + Cisplatin + RT | 02 | N | 10535889 | CAPECITABINE + TRASTUZUMAB |
| 10004583 | 10008199 | 0 | 90.8 | Palliative (P) | 2018-05-26 | 2018-05-27 | IRINOTECAN + MDG + PANITUMUMAB | 2 | N | 10536150 | DABRAFENIB + TRAMETINIB |
| 10004584 | 10002895 | null | 91.1 | null | 2019-02-18 | 2019-02-21 | Cisplatin + Docetaxel +Fluorouracil | N | null | 10536168 | ARISTOTLE TRIAL |
| 10004585 | 10002895 | 1.6 | 76 | Adjuvant (A) | 2017-11-29 | 2017-12-01 | BEAM | N | N | 10536168 | CISPLATIN + VINORELBINE + RT |
| 10004586 | 10002896 | 1.8 | null | Adjuvant (A) | 2018-02-17 | 2018-02-17 | METHOTREXATE | 2 | N | 10536356 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 10004587 | 10002897 | 1.8 | 89.3 | Palliative (P) | null | 2015-03-28 | IBRUTINIB | N | N | 10536360 | CYCLOPHOSPHAMIDE |
| 10004588 | 10002897 | null | 76 | Neo-adjuvant (N) | 2018-05-20 | 2018-06-10 | MITOMYCIN | 2 | N | 10536360 | MITOMYCIN |
| 10004589 | 10002898 | 1.67 | null | Not known (9) | 2016-09-28 | 2016-09-28 | Gefitinib: 1 to 2 & 4 onwards | Y | N | 10536441 | IPILIMUMAB |
| 10004590 | 10002899 | 1.78 | 92.1 | Adjuvant (A) | 2014-03-16 | 2014-04-19 | QUASAR 2 TRIAL | 2 | Y | 10536442 | CARBOPLATIN + RT |
| 10004591 | 10002900 | 1.53 | 70.2 | Neo-adjuvant (N) | 2018-08-11 | 2018-08-11 | Cyclophosphamide + Docetaxel | 02 | N | 10536543 | CHLORAMBUCIL + RITUXIMAB |
| 10004592 | 10002900 | 1.71 | 68 | null | 2016-11-04 | 2016-11-10 | FCR | N | N | 10536543 | MITOMYCIN |
| 10004593 | 10002900 | 1.78 | 95 | null | 2017-03-31 | 2017-04-03 | MPT | N | N | 10536543 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004594 | 10002901 | 1.68 | 95 | Palliative (P) | 2018-10-22 | 2018-11-08 | DHAP - R | 2 | N | 10536766 | DACARBAZINE |
| 10004595 | 10002901 | 1.55 | 70.6 | Palliative (P) | 2013-12-16 | 2014-01-15 | null | Y | N | 10536766 | CHLORAMBUCIL + RITUXIMAB |
| 10004596 | 10002901 | null | null | Palliative (P) | 2017-07-11 | 2017-08-05 | Bendamustine + prednisolone | 02 | Y | 10536766 | CAPECITABINE + MITOMYCIN + RT |
| 10004597 | 10002901 | 1.6 | null | Palliative (P) | 2017-09-23 | 2017-09-23 | Cisplatin + Docetaxel +Fluorouracil | N | null | 10536766 | FLUOROURACIL + MITOMYCIN |
| 10004598 | 10002901 | 1.75 | null | Neo-adjuvant (N) | 2018-12-22 | 2018-12-30 | Cyclophosphamide + Docetaxel | null | N | 10536766 | PAZOPANIB |
| 10004599 | 10002902 | 1.72 | 78 | Palliative (P) | 2016-05-14 | 2016-05-19 | MPT | 2 | N | 10537298 | HCX |
| 10004600 | 10002903 | 1.68 | 82.1 | null | 2018-01-01 | 2018-01-07 | Bendamustine +/- Prednisolone | N | N | 10537309 | FCR |
| 10004601 | 10002904 | 1.78 | 64.1 | Disease modification (D) | 2018-01-04 | 2018-01-05 | Capecitabine + Cisplatin + RT | null | N | 10537310 | DOXORUBICIN EMBOLISATION |
| 10004602 | 10002904 | 1.73 | 77.8 | Adjuvant (A) | 2017-08-26 | 2017-09-19 | Sunitinib | 02 | N | 10537310 | LENALIDOMIDE |
| 10004603 | 10002904 | 1.74 | 94.4 | Adjuvant (A) | 2018-04-27 | 2018-04-29 | Cetuximab + FOLFIRI cycle1 | null | N | 10537310 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN |
| 10004604 | 10002905 | null | 70.8 | Disease modification (D) | 2018-11-06 | 2019-01-29 | ECF | N | N | 10537520 | TAC |
| 10004605 | 10002905 | 1.61 | 61.8 | Palliative (P) | 2015-10-12 | 2015-10-13 | CARFILZOMIB + CYCLOPHOSPHAMIDE | 02 | N | 10537520 | CAPECITABINE + MITOMYCIN |
| 10004606 | 10002906 | 1.65 | 60.7 | null | 2014-11-21 | 2014-11-21 | CISPLATIN + VINORELBINE + RT | 2 | null | 10537534 | BEP |